AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting ...

Research shows Fc–IL-4 revitalizes exhausted CD8+ T cells, boosting antitumor responses and highlighting the potential of ...

By killing a certain proportion of actively dividing CAR-T cells, the secretion of inflammatory cytokines by chimeric T cells is reduced while retaining the efficacy of unaffected T cells. The Aveni ...

Human innate immune cells that “remember” previous stimulation could provide new insights into chronic inflammatory diseases.

Receiving CAR-T cell therapies in an outpatient setting may be safe and feasible without intensive remote monitoring with an early cytokine release syndrome (CRS) intervention strategy in patients ...

Researchers sought to determine whether CAR-T therapy would be effective in patients with RRMM and light chain amyloidosis.

Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company ...

In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community ...

Tocilizumab -- an interleukin (IL)-6 receptor inhibitor -- was approved by the FDA in 2017 for the treatment of severe or ...